Jesse Shefferman - Jan 19, 2023 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Role
CEO and President, Director
Signature
/s/ Mary Grendell, Attorney-In-Fact
Stock symbol
TARA
Transactions as of
Jan 19, 2023
Transactions value $
$0
Form type
4
Date filed
1/20/2023, 03:00 PM
Previous filing
Jan 11, 2023
Next filing
Jun 27, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARA Common Stock Award $0 +51.3K +5.92% $0.00 918K Jan 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARA Stock Option (Right to Buy) Award $0 +308K $0.00 308K Jan 19, 2023 Common Stock 308K $3.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023.
F2 25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.